IL102640D0 - Recombinant antibodies for human therapy - Google Patents

Recombinant antibodies for human therapy


Publication number
IL102640D0 IL10264092A IL10264092A IL102640D0 IL 102640 D0 IL102640 D0 IL 102640D0 IL 10264092 A IL10264092 A IL 10264092A IL 10264092 A IL10264092 A IL 10264092A IL 102640 D0 IL102640 D0 IL 102640D0
Prior art keywords
recombinant antibodies
human therapy
Prior art date
Application number
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US73506491A priority Critical
Priority to US85628192A priority
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of IL102640D0 publication Critical patent/IL102640D0/en
First worldwide family litigation filed litigation Critical "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.


IL10264092A 1991-07-25 1992-07-24 Recombinant antibodies for human therapy IL102640D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US73506491A true 1991-07-25 1991-07-25
US85628192A true 1992-03-23 1992-03-23

Publications (1)

Publication Number Publication Date
IL102640D0 true IL102640D0 (en) 1993-01-14



Family Applications (1)

Application Number Title Priority Date Filing Date
IL10264092A IL102640D0 (en) 1991-07-25 1992-07-24 Recombinant antibodies for human therapy

Country Status (24)

Country Link
EP (3) EP1715045A3 (en)
JP (1) JP3048640B2 (en)
KR (1) KR0137806B1 (en)
AP (1) AP307A (en)
AT (2) AT327331T (en)
AU (1) AU673499B2 (en)
BG (1) BG62656B1 (en)
BR (1) BR9206313A (en)
CA (1) CA2114015C (en)
CZ (1) CZ289472B6 (en)
DE (4) DE69233011D1 (en)
DK (2) DK1266965T3 (en)
ES (2) ES2265005T3 (en)
FI (1) FI117703B (en)
HU (2) HUT70272A (en)
IL (1) IL102640D0 (en)
MY (1) MY121185A (en)
NO (1) NO318097B1 (en)
NZ (1) NZ243706A (en)
OA (1) OA9879A (en)
PT (1) PT100735B (en)
RO (1) RO116404B1 (en)
SK (2) SK285046B6 (en)
WO (1) WO1993002108A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
NZ243558A (en) * 1991-07-15 1994-06-27 Wellcome Found Recombinant primate antibodies and their production
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE122004000036I1 (en) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP0703925B1 (en) 1993-06-03 1999-08-18 Therapeutic Antibodies Inc. Production of antibody fragments
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5855888A (en) * 1994-04-26 1999-01-05 Kanebo, Ltd. Drug for the treatment of rheumatoid arthritis
DE69519997D1 (en) * 1994-10-25 2001-03-01 Glaxo Group Ltd Using bind reagents against CD23 in the treatment of autoimmune diseases
CZ172497A3 (en) * 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
ES2230848T3 (en) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity.
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522511A (en) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション Combination therapy b-cell lymphoma comprising administration of anti-cd20 antibody
EP2055313B1 (en) 1998-11-09 2015-04-29 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
EP1642596A3 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP2151493B1 (en) * 2000-07-03 2012-06-13 Catalent Pharma Solutions, LLC Host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1297168A2 (en) * 2000-07-03 2003-04-02 Gala Design, Inc. Expression vectors
US7250165B2 (en) 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
PL216630B1 (en) 2002-10-17 2014-04-30 Genmab A/S Human monoclonal antibodies against cd20
CN1902228A (en) * 2003-11-07 2007-01-24 安姆根有限公司 Monkey immunoglobulin sequences
JP5027512B2 (en) 2003-11-14 2012-09-19 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Immunomodulation
BRPI0509367A (en) 2004-03-30 2007-09-11 Glaxo Group Ltd antibody, antigen binding fragment, pharmaceutical composition, methods of treating a human patient afflicted with a disease or disorder, screening an antibody, and detecting hosm in a biological sample, use of a therapeutic antibody or antigen binding fragment, drug, vector, polynucleotide, stably transformed or transfected recombinant host cell, and process for the manufacture of a therapeutic antibody
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー/エスGenmab A/S Human monoclonal antibody against CD20
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US8962278B2 (en) * 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
RU2008110060A (en) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Designed antibodies with frame sections of primates of the new light
JP2009504686A (en) * 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド Chimeric antibodies using the New World primate domain
WO2007070948A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
KR20090039666A (en) 2006-02-01 2009-04-22 아라나 테라퓨틱스 리미티드 Domain antibody construct
CA2661446C (en) 2006-08-11 2017-11-21 Csl Limited Treatment of pulmonary disease conditions
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
DK2066349T3 (en) 2006-09-08 2012-07-09 Medimmune Llc Humanized anti-cd19 antibodies and use thereof in treatment of tumors, transplantation and autoimmune diseases
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
CA2666682C (en) 2006-10-19 2014-07-08 Merck & Co., Inc. Anti-il-13r.alpha.1 antibodies and their uses thereof
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
CL2008002092A1 (en) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugate containing two or more antifusogenic peptides and an anti-CD-4 antibody; Method of production; pharmaceutical composition comprising the same; Polypeptides antifusogenic conjugate and use to treat viral infections.
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2646470T3 (en) 2010-11-30 2017-07-31 F.Hoffmann-La Roche Ag Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
US20140301675A1 (en) * 2011-10-31 2014-10-09 Jan-Niklas Keltsch Packaging for single-handed manipulation
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
AU2018206552A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243558A (en) * 1991-07-15 1994-06-27 Wellcome Found Recombinant primate antibodies and their production

Also Published As

Publication number Publication date
DE69233011D1 (en) 2003-05-22
AT327331T (en) 2006-06-15
FI940336A (en) 1994-03-10
AU673499B2 (en) 1996-11-14
ES2265005T3 (en) 2007-02-01
JP3048640B2 (en) 2000-06-05
RO116404B1 (en) 2001-01-30
DK605442T3 (en)
BR9206313A (en) 1995-04-11
FI940336A0 (en) 1994-01-24
PT100735A (en) 1993-10-29
MY121185A (en) 2006-01-28
PT100735B (en) 1999-07-30
AT237638T (en) 2003-05-15
DK1266965T3 (en) 2006-09-25
SK285046B6 (en) 2006-05-04
AU2425592A (en) 1993-02-23
CA2114015A1 (en) 1993-02-04
EP0605442A1 (en) 1994-07-13
EP1266965A3 (en) 2003-01-02
SK285960B6 (en) 2007-12-06
NZ243706A (en) 1994-08-26
FI117703B (en) 2007-01-31
EP1715045A3 (en) 2006-12-13
EP0605442B1 (en) 2003-04-16
EP1715045A2 (en) 2006-10-25
CZ14994A3 (en) 1994-07-13
FI117703B1 (en)
CZ289472B6 (en) 2002-01-16
DK0605442T3 (en) 2003-08-04
EP0605442A4 (en) 1995-07-12
DE69233628T2 (en) 2007-04-26
OA9879A (en) 1994-09-15
SK8894A3 (en) 1994-09-07
KR0137806B1 (en) 1998-04-30
HU211881A9 (en) 1995-12-28
CA2114015C (en) 2002-12-10
DE69233628D1 (en) 2006-06-29
FI940336D0 (en)
JPH06509708A (en) 1994-11-02
AP9200413A0 (en) 1992-07-31
NO940219D0 (en) 1994-01-21
HU9400201D0 (en) 1994-05-30
BG62656B1 (en) 2000-04-28
WO1993002108A1 (en) 1993-02-04
NO318097B1 (en) 2005-01-31
AP307A (en) 1994-01-31
EP1266965A2 (en) 2002-12-18
NO940219L (en) 1994-03-25
EP1266965B1 (en) 2006-05-24
ES2196002T3 (en) 2003-12-16
HUT70272A (en) 1995-09-28
BG98411A (en) 1995-02-28
DE69233011T2 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
US5518998C1 (en) Therapeutic preparation for inhalation
ZA9208511B (en) Peptides
HK59396A (en) Modified human g-csf
HU9600281D0 (en) Therapeutic peptide derivatives
AU648037B2 (en) Therapeutic peptides
GB8906166D0 (en) Therapeutic agents
HUT70258A (en) Reconstituted human antibody against interleukin 6 receptor
IL101818D0 (en) Therapeutic agent
GB8926512D0 (en) Therapeutic agents
HU9501841D0 (en) Therapeutic combination containing interferon
GB8917069D0 (en) Therapeutic agents
IL100365D0 (en) Monoclonal antibodies against human tumor necrosis factor alpha
HU910369D0 (en) Medical preparation
GB9013750D0 (en) Therapeutic agents
GR3027613T3 (en) Recombinant immunoconjugates for therapy comprising interleukin 2
YU163289A (en) Recombinant animal somatotropine
GB9416442D0 (en) Therapeutic heterocycles
IL107025D0 (en) Recombinant multivalent m protein vaccine
GB8820844D0 (en) Therapeutic agents
GB9113809D0 (en) Papillomavirus l2 protein
GB9022785D0 (en) Therapeutic agents
IL105930D0 (en) Therapeutic respiration device
IE922161A1 (en) Healing dressing
AP9000234A0 (en) Therapeutic nucleocides
IE922122A1 (en) Delayed therapy

Legal Events

Date Code Title Description
FF Patents granted
KB Patents renewed
MM9K Patent not in force due to non-payment of renewal fees